Oncology innovation is accelerating across therapeutic modalities, precision medicine, biomarkers and artificial intelligence. But as scientific possibilities expand, the growing challenge for sponsors is determining what is ready to move forward and how to make critical oncology drug development decisions with greater confidence. Increasingly, that means evaluating not only scientific promise, but whether innovations can be scaled across geographies, complex patient populations and regulatory environments to support successful global clinical development programs. This webinar will examine how to assess which advances are development-ready and translate them into scalable global strategies. Ahead of the 2026 European Society for Medical Oncology (ESMO) Congress, Syneos Health® surveyed the oncology community to understand where leaders see the greatest opportunities and challenges in oncology clinical development. Responses highlighted strong interest in emerging scientific advances while reinforcing the need for practical guidance on trial design, execution and development strategy. That reflects a broader industry reality: breakthrough science is advancing rapidly, but sponsors must still determine which innovations are ready to scale and how to translate scientific promise into clinical development and commercial impact. That tension will anchor this webinar. Following a brief, data-led presentation, oncology experts will examine what separates promising oncology innovation from development-ready science, and what it takes to translate emerging breakthroughs into scalable clinical trial and drug development strategies. The conversation will look beyond individual ESMO readouts to ask a more consequential question: Which advances are truly ready to move oncology drug development forward, and what should sponsors be doing now to accelerate